These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15197303)

  • 1. Chemical production of bispecific antibodies.
    Graziano RF; Guptill P
    Methods Mol Biol; 2004; 283():71-85. PubMed ID: 15197303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to make bispecific antibodies.
    French RR
    Methods Mol Med; 2000; 40():333-9. PubMed ID: 21337104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.
    Glennie MJ; McBride HM; Worth AT; Stevenson GT
    J Immunol; 1987 Oct; 139(7):2367-75. PubMed ID: 2958547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering Fab' fragments for efficient F(ab)2 formation in Escherichia coli and for improved in vivo stability.
    Rodrigues ML; Snedecor B; Chen C; Wong WL; Garg S; Blank GS; Maneval D; Carter P
    J Immunol; 1993 Dec; 151(12):6954-61. PubMed ID: 7903100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of bifunctional antibodies for immunoassays.
    DeSilva BS; Wilson GS
    Methods; 2000 Sep; 22(1):33-43. PubMed ID: 11020315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification of antibody Fab and F(ab')2 fragments using Gradiflow technology.
    Cheung GL; Thomas TM; Rylatt DB
    Protein Expr Purif; 2003 Nov; 32(1):135-40. PubMed ID: 14680950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid phase synthesis of bifunctional antibodies.
    DeSilva BS; Wilson GS
    J Immunol Methods; 1995 Dec; 188(1):9-19. PubMed ID: 8551042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95.
    Herrmann T; Grosse-Hovest L; Otz T; Krammer PH; Rammensee HG; Jung G
    Cancer Res; 2008 Feb; 68(4):1221-7. PubMed ID: 18281499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time resolved native ion-mobility mass spectrometry to monitor dynamics of IgG4 Fab arm exchange and "bispecific" monoclonal antibody formation.
    Debaene F; Wagner-Rousset E; Colas O; Ayoub D; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
    Anal Chem; 2013 Oct; 85(20):9785-92. PubMed ID: 24007193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments.
    Béduneau A; Saulnier P; Hindré F; Clavreul A; Leroux JC; Benoit JP
    Biomaterials; 2007 Nov; 28(33):4978-90. PubMed ID: 17716725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of bispecific and trispecific F(ab)2 and F(ab)3 antibody derivatives.
    French RR
    Methods Mol Biol; 1998; 80():121-34. PubMed ID: 9664369
    [No Abstract]   [Full Text] [Related]  

  • 12. Antibody-directed fibrinolysis: a bispecific (Fab')2 that binds to fibrin and tissue plasminogen activator.
    Runge MS; Bode C; Savard CE; Matsueda GR; Haber E
    Bioconjug Chem; 1990; 1(4):274-7. PubMed ID: 2129015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immobilization of antibody fragment for immunosensor application based on surface plasmon resonance.
    Lee W; Oh BK; Lee WH; Choi JW
    Colloids Surf B Biointerfaces; 2005 Feb; 40(3-4):143-8. PubMed ID: 15708503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covalent modifications of antitetanus F(ab')2 fragments with natural and synthetic polyamines and their effects on the antibody endocytosis in cultured HL60 cells.
    Hervé F; Ghinea N; D'Athis P; Carrupt PA; Scherrmann JM
    Bioconjug Chem; 2008 Aug; 19(8):1543-55. PubMed ID: 18630939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant approaches to IgG-like bispecific antibodies.
    Marvin JS; Zhu Z
    Acta Pharmacol Sin; 2005 Jun; 26(6):649-58. PubMed ID: 15916729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays.
    Jones RG; Alsop TA; Hull R; Tierney R; Rigsby P; Holley J; Sesardic D
    Toxicon; 2006 Sep; 48(3):246-54. PubMed ID: 16870221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific rabbit Fab'-bovine serum albumin conjugate used in hemagglutination immunoassay for beta-microseminoprotein.
    Yukawa N; Osawa M; Saito T; Hasegawa T; Matsuda H; Takahama K; Takeichi S
    J Immunoassay; 1997 Aug; 18(3):215-33. PubMed ID: 9257262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged in vivo residence times of antibody fragments associated with albumin.
    Smith BJ; Popplewell A; Athwal D; Chapman AP; Heywood S; West SM; Carrington B; Nesbitt A; Lawson AD; Antoniw P; Eddelston A; Suitters A
    Bioconjug Chem; 2001; 12(5):750-6. PubMed ID: 11562193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cysteine-SILAC Mass Spectrometry Enabling the Identification and Quantitation of Scrambled Interchain Disulfide Bonds: Preservation of Native Heavy-Light Chain Pairing in Bispecific IgGs Generated by Controlled Fab-arm Exchange.
    van den Bremer ETJ; Labrijn AF; van den Boogaard R; Priem P; Scheffler K; Melis JPM; Schuurman J; Parren PWHI; de Jong RN
    Anal Chem; 2017 Oct; 89(20):10873-10882. PubMed ID: 28922593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies.
    Shen J; Vil MD; Jimenez X; Iacolina M; Zhang H; Zhu Z
    J Biol Chem; 2006 Apr; 281(16):10706-14. PubMed ID: 16481314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.